ERG and prostate carcinoma: Results of an in vivo study in these cells showed a significantly reduced expression of TMPRSS2 in malignant cells harboring TMPRSS2–ERG fusion, but not in prostate cancer cells without TMPRSS2–ERG fusion [41].